CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 50 enrolled
Drug / intervention
VFIdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03808948
NCT03808948N/ACompleted
CompareCT.gov

Estimating Versus Measuring Plasma Volume and Kidney Function in Acute Decompensated Congestive Heart Failure (EMPaKT-CHF)

Charite University, Berlin, Germany·interventional·Posted Jan 18, 2019·Updated Nov 17, 2021

In Brief

A clinical study evaluating VFI for CHF. Completed, enrolled 50 participants across 1 site.

Detailed Summary

This is an investigator-initiated, one-armed, phase 2 clinical trial using an injectable fluorescent tracer to assay and evaluate measured plasma volume (mPV) and measured glomerular filtration rate (mGFR) in hospitalized patients with acute decompensated congestive heart failure (CHF).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCHF
CountriesGermany
CollaboratorsFAST BioMedical

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedJan 18, 2019
Enrollment StartJan 10, 2019
Primary CompletionAug 17, 2019
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 7.5 years ago

Interventions

VFIdevice

The IV-administered visible fluorescent injectate (VFI)™ agent comprises a mixture of 2 different molecular weight carboxymethyl dextran molecules (5 kD and 150 kD) with different fluorescent dye molecules attached.